Rivaroxaban contains not less than 98.0% and not more than 102.0% of C19H18CLN3O5S, calculated on the anhydrous substance.

共有 1 個藥物證書使用此成份

利伐抑凝因
Rivaroxaban

• 申請商: 盛佳國際股份有限公司
• 適應症: 抗凝血劑。
• 發證日期: 2023-08-02